SCHEMBL27095908

SCHEMBL27095908

COc1ccc2cc(NCc3ccc(NCC4CCN(C)CC4)nc3)ccc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 2/20 0.44
CHEK1 O14757 1/20 0.44
JAK1 P23458 6/20 0.44
JAK2 O60674 4/20 0.43
JAK3 P52333 2/20 0.43
CCND3 P30281 2/20 0.42
CDK6 Q00534 2/20 0.42
CCNT1 O60563 3/20 0.42
GSK3B P49841 1/20 0.41
CDK9 P50750 2/20 0.41
PRKCQ Q04759 1/20 0.41
ACHE P22303 1/20 0.41
BACE1 P56817 1/20 0.41
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
TP53 P04637 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27096074 0.91 JAK1 (0.42) UTS2RCHEK1JAK1JAK2JAK3
SCHEMBL27095897 0.84 CHEK1 (0.43) UTS2RCHEK1JAK1JAK2CCNT1
SCHEMBL27095816 0.82 HDAC6 (0.45) CHEK1CCNT1CDK9NPC1
SCHEMBL27096057 0.81 CCNT1 (0.40) CHEK1CCNT1CDK9KDM4EHSD17B10
SCHEMBL27095817 0.81 HTR1A (0.49) JAK1JAK2JAK3GSK3B
SCHEMBL24493550 0.80 MRGPRX1 (0.44) CCNT1CDK9
SCHEMBL27095922 0.80 CCNT1 (0.47) CHEK1JAK1JAK2JAK3CCND3
SCHEMBL27096121 0.80 CHEK1 (0.41) CHEK1JAK1JAK2CCNT1CDK9
SCHEMBL24493457 0.80 CCNT1 (0.42) CCNT1CDK9HRH4
SCHEMBL27095996 0.79 HDAC6 (0.45) CCNT1KDM4ENPC1ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240059691-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2024-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240059691-A1 ENZYME INHIBITORS SERPINB1, XDH, ACE UTS2R 2417/4885CHEK1 3686/4885JAK1 2844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.